Zanidatamab Triplet Shows Positive PFS Outcomes in HR+/HER2+ Metastatic Breast Cancer

Zanidatamab in combination with palbociclib and fulvestrant resulted in positive progression-free survival outcomes and exhibited an acceptable safety profile in patients with hormone receptor–positive, HER2-positive metastatic breast cancer.

Related Keywords

Spain ,San Antonio ,Texas ,United States ,Barcelona ,Comunidad Autonoma De Cataluna ,Hebron ,Israel General ,Israel , ,Hebron Institute Of Oncology ,Hebron University Hospital ,Antonio Breast Cancer ,Santiago Escriv ,Hebron Institute ,Sabcs ,San Antonio Breast Cancer Symposium ,Her2 Positive ,Hr Positive ,Metastatic Breast Cancer ,